SLIGKV-NH2 - CAS 190383-13-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C28H54N8O7
Molecular Weight:
614.78
COA:
Inquire
Targets:
Protease-Activated Receptors (PARs)
Description:
SLIGKV-NH2 is a protease-activated receptor 2 (PAR2) agonist (Ki = 9.64 μM; IC50 = 10.4 μM).
Brife Description:
PAR2 agonist
Sequence:
Ser-Leu-Ile-Gly-Lys-Val
Synonyms:
PAR2 activating peptide; PAR2-AP; PAR-2 (1-6) Human
MSDS:
Inquire
InChIKey:
HOWDUIVVWDUEED-WAUHAFJUSA-N
InChI:
InChI=1S/C28H54N8O7/c1-7-17(6)23(36-27(42)20(12-15(2)3)34-25(40)18(30)14-37)28(43)32-13-21(38)33-19(10-8-9-11-29)26(41)35-22(16(4)5)24(31)39/h15-20,22-23,37H,7-14,29-30H2,1-6H3,(H2,31,39)(H,32,43)(H,33,38)(H,34,40)(H,35,41)(H,36,42)/t17-,18-,19-,20-,22-,23-/m0/s1
Canonical SMILES:
CCC(C)C(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CO)N
1.Proteinase-activated receptors 1 and 2 mediate contraction of human oesophageal muscularis mucosae.
Chang BS;Chang JC;Huang SC Neurogastroenterol Motil. 2010 Jan;22(1):93-7, e32. doi: 10.1111/j.1365-2982.2009.01380.x. Epub 2009 Aug 20.
Proteinase-activated receptors 1 and 2 mediate contraction of the human gallbladder. In the present study, we investigated effects mediated by proteinase-activated receptors (PARs) in the human oesophagus by measuring contraction of muscularis mucosae strips isolated from the human oesophagus. Both PAR(1) agonists (thrombin, SFLLRN-NH(2) and TFLLR-NH(2)) and PAR(2) agonists (trypsin, 2-furoyl-LIGRLO-NH(2) and SLIGKV-NH(2)) caused concentration-dependent contraction. In contrast, PAR(1) and PAR(2) control peptides did not cause contraction. The existence of PAR(1) and PAR(2) in the human oesophageal muscularis mucosae was confirmed by immunohistochemistry and reverse transcription-polymerase chain reaction. On the other hand, PAR(4) agonists, GYPGKF-NH(2), GYPGQV-NH(2) and AYPGKF-NH(2), did not cause contraction or relaxation in resting or carbachol-contracted muscularis mucosae strips, suggesting that PAR(4) is not involved in human oesophageal motility. The contractile responses to SFLLRN-NH(2) and trypsin in the human oesophagus were insensitive to atropine and tetrodotoxin, indicating that the contractile response was not neurally mediated. Taken together, these results demonstrate that PAR(1) and PAR(2) but not PAR(4) mediate contraction in human oesophageal muscularis mucosae.
2.Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells.
Vesey DA;Cheung CW;Kruger WA;Poronnik P;Gobe G;Johnson DW Kidney Int. 2005 Apr;67(4):1315-29.
BACKGROUND: ;Fibrin deposition is frequently observed within the tubulointerstitium in various forms of chronic renal disease. This suggests the presence of active components of the coagulation pathway, which may contribute to the progressive deterioration in renal function. The aim of this study was to investigate the proinflammatory and fibroproliferative effects of the coagulation protease thrombin on human proximal tubular cells (PTC) in culture.;METHODS: ;Primary cultures of PTC were established from normal kidney tissue and grown under serum-free conditions with or without thrombin or the protease-activated receptor (PAR) activating peptides TFLLRN-NH(2), SLIGKV-NH(2), and SFLLRN-NH(2) (100 to 400 micromol/L). DNA synthesis (thymidine incorporation), intracellular Ca(2+) mobilization (fura-2 fluorimetry), fibronectin secretion [enzyme-linked immunosorbent assay (ELISA), immunoblotting], monocyte chemoattractant protein-1 (MCP-1) secretion (ELISA), and transforming growth factor-beta1 (TGF-beta1) secretion (ELISA) were measured. Reverse transcription-polymerase chain reaction (RT-PCR) was used to assess PAR mRNA expression in these cells.;RESULTS: ;Thrombin enhanced DNA synthesis, fibronectin secretion, MCP-1 secretion, and TGF-beta1 secretion in a concentration-dependent manner.
3.Proteinase-activated receptor 2 (PAR(2)): development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)- and PAR(2)-derived peptide ligands.
Al-Ani B;Saifeddine M;Kawabata A;Renaux B;Mokashi S;Hollenberg MD J Pharmacol Exp Ther. 1999 Aug;290(2):753-60.
A cloned rat proteinase-activated receptor (PAR)(2)-expressing cell line (KNRK-rPAR(2)) was used to study the structure-activity relationships (elevated intracellular Ca(2+)) for a series of: 1) PAR(1)-derived receptor-activating ligands (PAR(1)-APs) [SFLLR (P5), SFLLR-NH(2) (P5-NH(2)), SFLLRNP (P7), SFLLRNP-NH(2) (P7-NH(2)), and TFLLR-NH(2) (TF-NH(2))] and 2) PAR(2)-derived-activating-peptides (PAR(2)-APs) [SLIGRL-NH(2) (SL-NH(2)), SLIGR-NH(2) (GR-NH(2)), and SLIGKV-NH(2) (KV-NH(2))]. The activities of the PAR-APs were compared with the PAR(2)-AP analog trans-cinnamoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH(2) tc-NH(2)), which as a [(3)H]propionyl derivative ([(3)H]propionyl-tc-NH(2)) was used to develop a radioligand-binding assay for PAR(2). The relative potencies of the PAR-APs in the Ca(2+)-signaling assay were tc-NH(2) = SL-NH(2) > KV-NH(2) congruent with P5-NH(2) > GR-NH(2) > P7-NH(2) > P7 > P5 > TF-NH(2). The reverse sequence PAR-APs, LSIGRL-NH(2) (LS-NH(2)), LRGILS-NH(2) (LR-NH(2)), FSLLRY-NH(2) (FSY-NH(2)), and FSLLR-NH(2) (FS-NH(2)), as well as the Xenopus PAR(1)-AP TFRIFD-NH(2), were inactive. The relative biological potencies of the peptides were in accord with their ability to compete for the binding of [(3)H]propionyl-tc-NH(2) (tc-NH(2) = SL-NH(2) > GR-NH(2) congruent with P5-NH(2) > P5) to KNRK-rPAR(2) cells, whereas inactive peptides (FS-NH(2); LR-NH(2)) showed no appreciable binding competition.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Protease-Activated Receptors (PARs) Products


Atopaxar
(CAS: 751475-53-3)

Atopaxar is a Protease-activated receptor-1 (PAR-1) inhibitor. It can inhibit the binding of a high-affinity thrombin receptor-activating peptide ([(3)H]haTRAP)...

CAS 245329-01-5 LRGILS-NH

LRGILS-NH
(CAS: 245329-01-5)

LRGILS-NH is a control peptide for SLIGRL-NH2, a protease-activated receptor-2 (PAR2) agonist that facilitates gastrointestinal transit in vivo.

CAS 474550-69-1 E 5555 hydrobromide

E 5555 hydrobromide
(CAS: 474550-69-1)

E 5555 hydrobromide is a potent and orally bioactive thrombin receptor (or protease-activated receptor 1, PAR1) antagonist (IC50 = 19 nM). It inhibits human pla...

CAS 327177-34-4 tcY-NH2

tcY-NH2
(CAS: 327177-34-4)

tcY-NH2 is a selective PAR4 antagonist peptide that inhibits aggregation caused by receptor-activating peptide analogs (GY-NH2, AY-NH2) and thrombin.

CAS 942413-05-0 VKGILS-NH2

VKGILS-NH2
(CAS: 942413-05-0)

VKGILS-NH2 is a reversed control peptide for SLIGKV-NH2, which is a protease-activated receptor 2 (PAR2) agonist.

CAS 173904-50-2 FR 171113

FR 171113
(CAS: 173904-50-2)

FR 171113 is a protease-activated receptor 1 (PAR1) antagonist displaying significant antiplatelet activity in vitro. It inhibits thrombin TRAP-6-induced platel...

CAS 190383-13-2 SLIGKV-NH2

SLIGKV-NH2
(CAS: 190383-13-2)

SLIGKV-NH2 is a protease-activated receptor 2 (PAR2) agonist (Ki = 9.64 μM; IC50 = 10.4 μM).

CAS 1216720-69-2 SCH 79797 dihydrochloride

SCH 79797 dihydrochloride
(CAS: 1216720-69-2)

SCH 79797 dihydrochloride is a potent and selective non-peptide PAR1 receptor antagonist (IC50 = 70 nM). SCH 79797 blocks haTRAP-induced human platelet aggregat...

CAS 141136-83-6 Thrombin Receptor Activator Peptide 6

Thrombin Receptor Activator Peptide 6
(CAS: 141136-83-6)

TRAP-6, a peptide compound, has been found to be a PAR1 agonist and could also influence the phosphorylation of rapid phosphodiesterase 3A in the positive way.

CAS 1051487-82-1 AC 264613

AC 264613
(CAS: 1051487-82-1)

AC 264613 is a potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 7.5). AC 264613 inhibits interferon regulatory factor 5 and decreases ...

CAS 916170-19-9 AC-55541

AC-55541
(CAS: 916170-19-9)

AC-55541 is a novel small-molecule protease-activated receptor 2(PAR2) agonist which displays no activity at other PAR subtypes or at over 30 other receptors in...

CAS 618385-01-6 Vorapaxar

Vorapaxar
(CAS: 618385-01-6)

SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis. It is currently un...

CAS 245329-02-6 FSLLRY-NH2

FSLLRY-NH2
(CAS: 245329-02-6)

FSLLRY-NH2 is a selective PAR2 peptide antagonist. It reverses taxol-induced mechanical allodynia, heat hyperalgesia and PKC activation in ICR mice, also suppre...

CAS 729589-58-6 2-Furoyl-LIGRLO-amide

2-Furoyl-LIGRLO-amide
(CAS: 729589-58-6)

2-Furoyl-LIGRLO-amide is a potent and selective PAR2 receptor agonist (pD2 = 7.0). It causes a dose-dependent relaxation of murine femoral arteries.

BMS-986120
(CAS: 1478712-37-6)

BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vasc...

UDM-002555

UDM-002555 is a small-molecule and selective antagonist of protease-activated receptor-4 (PAR-4). It can suppress the activation of platelet in dose manner. In ...

CAS 1252806-86-2 GB 83

GB 83
(CAS: 1252806-86-2)

GB 83 is a selective antagonist of human protease activated receptor 2 (PAR2) (IC50 = 2 mM).

CAS 89159-60-4 ML 354

ML 354
(CAS: 89159-60-4)

ML 354 is a selective PAR4 antagonist with IC50 value of 140 nM.

CAS 171436-38-7 SLIGRL-NH

SLIGRL-NH
(CAS: 171436-38-7)

LIGRL-NH2 is a PAR2 activator with EC50 value of ~5 µM. It can be used to explore signaling through PAR2 in cells.

BMS-986141

BMS-986141 is a dual antagonist of proteinase-activated receptor 1 (PAR1) and PAR4. BMS-986141 was confirmed in cynomolgus monkeys to be a better therapy for pr...

Chemical Structure

CAS 190383-13-2 SLIGKV-NH2

Quick Inquiry

Verification code

Featured Items